Abstract:BACKGROUND Acute liver failure (ALF) is a significant and complex hepatic insult that may rapidly progress to life-threatening conditions. Recently, menstrual blood stem cells (MenSCs) have been identified as a group of easily accessible mesenchymal stem cells with the advantages of non-invasive acquisition, low immunogenicity, a greater capacity of self-renewal and multi-lineage differentiation, making them promising candidates for stem cell-based therapy to revolutionize the treatment strategies for liver failure. AIM To investigate the therapeutic potential of MenSCs for treating ALF in pigs and to dynamically trace the biodistribution of transplanted cells. METHODS MenSCs were labeled in vitro with PKH26, a lipophilic fluorescent dye. The treatment group received immediate transplantation of PKH26-labelled MenSCs (2.5 × 106/kg) via the portal vein after D-galactosamine injection, and the control group underwent sham operation. The survival time, liver function, and hepatic pathological changes were compared between the two groups. Three major organs (liver, lungs and spleen) were extracted from animals and imaged directly with the In vivo Imaging System (IVIS) at the predetermined time points. The regions of interest were drawn to quantify the cell uptake in different organs. RESULTS The labelling procedure did not affect the morphology, viability or multipotential differentiation of MenSCs. Biochemical analysis showed that the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL) and prothrombin time (PT) measured at selected time points 24 h after transplantation were significantly decreased in the treatment group (P < 0.05). The survival time of ALF animals was prolonged in the treatment group compared with the control group (75.75 ± 5.11 h vs 53.75 ± 2.37 h, log rank, P < 0.001). The liver pathological tissue in the MenSC treatment group showed obviously increased numbers of remaining hepatocytes and a comparatively slight necrotic degree and area. In addition, the IVIS imaging revealed that PKH26-positive MenSCs were clearly retained in the liver initially and then diffused through the systemic circulation. Interestingly, the signal intensity in the liver increased obviously at 36 h, which corresponded to the biochemical result that liver function deteriorated most rapidly at 24 - 36 h. CONCLUSION Our study demonstrates the therapeutic efficacy and homing ability of transplanted MenSCs in a large animal model of ALF and suggests that MenSC transplantation could be a promising strategy for treating ALF.

Intraportal mesenchymal stem cell transplantation prevents acute liver failure through promoting cell proliferation and inhibiting apoptosis.

The preliminarily investigation of therapeutic effects of mesenchymai stem cells on rat fulminant hepatic failure

Improvement of mesenchymal stromal cells and their derivatives for treating acute liver failure

Transplantation Routes and Mechanism of Mesenchymal Stem Cell Therapy in Porcine Models with Acute Liver Failure

Therapeutic Potential of Menstrual Blood Stem Cells in Treating Acute Liver Failure

The Effects of Conditioned Medium Derived from Mesenchymal Stem Cells Cocultured with Hepatocytes on Damaged Hepatocytes and Acute Liver Failure in Rats

Immediate Intraportal Transplantation of Human Bone Marrow Mesenchymal Stem Cells Prevents Death from Fulminant Hepatic Failure in Pigs

[Treatment of Acute Liver Injury by Intrasplenic Transplantation of Hepatic Stem Cells Combined with Heparin in Rats].

Human umbilical cord matrix stem cells efficiently rescue acute liver failure through paracrine effects rather than hepatic differentiation.

Mesenchymal Stem Cell Therapy in Acute Liver Failure

Combined mesenchymal stem cell transplantation and interleukin-1 receptor antagonism after partial hepatectomy.

The Beneficial Effect of Mesenchymal Stem Cells Transplantation in Combination with Interleukin-1 Receptor Antagonist on Post-Hepatectomy Liver Failure

Superior Performance of Co-Cultured Mesenchymal Stem Cells and Hepatocytes in Poly(lactic Acid-Glycolic Acid) Scaffolds for the Treatment of Acute Liver Failure.

Effect Evaluation of Interleukin-1 Receptor Antagonist Nanoparticles for Mesenchymal Stem Cell Transplantation.

Mesenchymal stem cells prolong survival and prevent lethal complications in a porcine model of fulminant liver failure

Combined therapy of mesenchymal stem cell transplantation and interleukin 1 receptor antagonist for swine acute liver failure

Human embryonic stem cell-derived immunity-and-matrix regulatory cells promote intrahepatic cell renewal to rescue acute liver failure

Study on transplantation of induced bone marrow mesenchymal stem cells via various route for the treatment of chronic liver injury

Porcine Adipose-Derived Mesenchymal Stem Cells Retain Their Stem Cell Characteristics and Cell Activities While Enhancing the Expression of Liver-Specific Genes after Acute Liver Failure

Intravenous injection of mesenchymal stem cells is effective in treating liver fibrosis

Transplantation of Mesenchymal Stem Cells Attenuates Acute Liver Failure in Mice Via an Interleukin-4-dependent Switch to the M2 Macrophage Anti-inflammatory Phenotype